Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
February 26, 2020 16:05 ET
|
Cyclacel
– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – ...